Evidence map›Paper›PMID 34798067›Full record

ArticleStem cell reports2021

In vitro expanded skeletal myogenic progenitors from pluripotent stem cell-derived teratomas have high engraftment capacity.

Ning Xie, Sabrina N Chu, Karim Azzag, Cassandra B Schultz, Lindsay N Peifer, Michael Kyba, Rita C R Perlingeiro, Sunny S K Chan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in cell and developmental biology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ning XieDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA; Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA; Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, USA.
Sabrina N ChuDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA.
Karim AzzagDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Cassandra B SchultzDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA.
Lindsay N PeiferDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA.
Michael KybaDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA; Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA; Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, USA.
Rita C R PerlingeiroStem Cell Institute, University of Minnesota, Minneapolis, MN, USA; Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, USA; Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sunny S K ChanDepartment of Pediatrics, University of Minnesota, 2231 6th Street SE, Cancer and Cardiovascular Research Building, Minneapolis, MN 55455 USA; Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA; Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, USA. Electronic address: sschan@umn.edu.
University of Minnesota · USMinneapolis Heart Institute Foundation · US

Funding

Skeletal Muscle Stem Cells Derived from TeratomasR01AR075413 · NIAMS · UNIVERSITY OF MINNESOTA · PI KYBA, MICHAEL · 2019 to 2023
$2.1M
Skeletal Muscle Regeneration from Pluripotent Stem CellsR01AR078571 · NIAMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2021 to 2025
$2.1M
Targeting Dystroglycanopathies using Pluripotent-derived Myogenic ProgenitorsR01AR071439 · NIAMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2017 to 2021
$1.9M
NIAMS NIH HHS R01 AR071439NIAMS NIH HHS R01 AR075413NIAMS NIH HHS R01 AR078571
6 · The paper itself

Abstract

One major challenge in realizing cell-based therapy for treating muscle-wasting disorders is the difficulty in obtaining therapeutically meaningful amounts of engraftable cells. We have previously described a method to generate skeletal myogenic progenitors with exceptional engraftability from pluripotent stem cells via teratoma formation. Here, we show that these cells are functionally expandable in vitro while retaining their in vivo regenerative potential. Within 37 days in culture, teratoma-derived skeletal myogenic progenitors were expandable to a billion-fold. Similar to their freshly sorted counterparts, the expanded cells expressed PAX7 and were capable of forming multinucleated myotubes in vitro. Importantly, these cells remained highly regenerative in vivo. Upon transplantation, the expanded cells formed new DYSTROPHIN

Indexed as

Muscle DevelopmentStem Cell TransplantationAnimalsCell CompartmentationCell DifferentiationCell ProliferationInduced Pluripotent Stem CellsMiceMuscle Fibers, SkeletalMuscle, SkeletalRNA-SeqTeratomaVascular Cell Adhesion Molecule-1Vascular Cell Adhesion Molecule-1cell therapymuscle stem cellsmuscular dystrophymyogenic differentiationpluripotent stem cells

Identifiers

PMID34798067
PMCPMC8693664
OpenAlexW3214461129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.